Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the Sonata® […]
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, a […]
Respected Leader in Medical Device Manufacturing and Engineering Management Redwood City, CA – March 30, 2017 – Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic uterine fibroids, today announced that medical device executive James Sparks has been named Vice President […]
First Health Economic Outcomes Research with Sonata Treatment to be Presented Redwood City, CA – Nov 10, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be […]
Increasing Body of Evidence Further Demonstrates Compelling Outcomes Redwood City, CA – October 19, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be featured in three […]
Company Expects to Submit Trial Results to FDA in Fourth Quarter of 2017 Redwood City, CA – October 18, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for treatment of benign uterine conditions, today announced the completion of enrollment in the SONATA Investigational Device Exemption (IDE) clinical trial, […]
Redwood City, CA – May 5, 2016 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that medical device executive Jiayu Chen, Ph.D., has been named Vice President of Engineering and Advanced Technologies, effective immediately. Dr. Chen reports directly to President and CEO Christopher […]
Accomplished Clinical Affairs Executive to Lead Clinical Research Initiatives and Programs Redwood City, CA – February 25, 2016 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that veteran clinical affairs executive Taraneh G. Farazi, Ph.D has been named Vice President, Clinical Affairs. Dr. […]
Novit Ventures LP Participates in Latest Round Redwood City, CA – November 17, 2015 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced $2.9 million of additional equity financing, increasing the aggregate amount raised to $46 million, completing this round of financing. Rockville, MD-based […]
Presentation on Early Clinical Response to Sonata™ System Selected as Best Abstract In New Instrumentation/Technology Category Redwood City, CA—November 12, 2015 – Gynesonics, Inc., a women’s health technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of uterine fibroids, announced today that its Sonata™ System technology […]
